Study of recombinant human IFN-α-2b bacilli calmette-guerin activated killer cells and against bladder cancer cell in vitro
Tóm tắt
Presently, one of the most potent immunotherapies is the application of bacillus Calmette Guerin (BCG) to prevent recurrences of the superficial bladder cancer. Despite its successful use, nonresponders and certain side effects remain a major obstacle. Therefore, current studies aim at developing recombinant BCG (rBCG) strains secreting Th1-like cytokines to improve the effectiveness of the therapy. In this study, a new type of rBCG strain constructed by Tianjin institute of Urology was tested for its immunostimulatory capacity in vitro. Peripheral blood monocytes (PBMC) were stimulated by recombinant BCG and transformed into bacilli Calmette-Guerin activated killer (BAK) cells, and the effect of anticancer BAK cells was studied. Recombinant IFN-α-2b-BCG, wild-type BCG (wBCG), wild-type BCG and IFN-α-2b were coincubated with PBMCs respectively in vitro, and the proliferation of PBMC was detected with MTT in different time. BAK cells have the ability to kill bladder tumor cells, and the antitumor activity of effecter cells was determined by LDH release assay. The result of MTT showed that the proliferation of PBMC in the recombinant BCG group was more powerful than in the other two groups (P < 0.05). The result of LDH release assay showed that the antitumor activity of BAK cells stimulated by Recombinant BCG was the highest in all groups. We conclude that the recombinant BCG can activate more PBMCs to anti-bladder cancer in vitro than wild-type BCG does.
Tài liệu tham khảo
Lam J S, Benson M C, O’Donnell M A, Sawczuk A, Gavazzi A, Wechsler M, Sawczuk I S. Bacillus Calmete-Guerin plus interferon-alpha 2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol, 2003, 21(5): 354–360
Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant α-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl, 1995, 67(4): 257–260
Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R. Bacillus Calmette-Gue’rin plus intravesical interferon α-2b in patients with superficial bladder cancer. Urology, 1996, 48(6): 957–961
Sarosdy M F, Kierum C A. Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J Urol, 1989, 142(5): 1376–1379
Riggs D R, Tarry W F, DeHaven J I, Sosnowski J, Lamm DL. Immunotherapy of murine transitional cell carcinoma of the bladder using α and γ interferon in combination with other forms of immunotherapy. J Urol, 1992, 147(1): 212–214
Hawkyard S J, James K, Prescott S, Jackson A M, Ritchie A W S, Smyth J F, Chisholm G D. The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol, 1991, 145: 1078–1081
Hawkyard S J, Jackson A M, James K, Prescott S, Smyth J F, Chisholm G D. The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol, 1992, 147(5): 1399–1403
Hawkyard S J, Jackson A M, Prescott S, James K, Chisholm G D. The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol, 1993, 150(2 Pt 1): 514–518
Kaplan D H, Shankaran V, Dighe A S, Stockert E, Aguet M, Old L J, Schreiber R D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 1998, 95(13): 7556–7561
Street S E, Cretney E, Smyth M J. Perforin and interferon-gamma activities independently control tumor initiation, growth and metastasis. Blood, 2001, 97(1): 192–197
Tzai T S, Lin S N. Interferon-alpha can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J Urol, 1992, 14(2): 523–527
Brinkmann V, Geiger T, Alkan S, Heusser C H. Interferon α increases the frequency of interferon γ-producing human CD41 T cells. J Exp Med, 1993, 178(5): 1655–1663
Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni M, Macchia D, Maggi E, Del Prete G, Romagnani S. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol, 1992, 149(9): 2977–2983
Brinkmann V, Heusser C H, Baer J, Kilchherr E, Erard F. Interferon α suppresses the capacity of T cells to help antibody production by human B cells. J Interferon Res, 1992, 12(4): 267–274
Peuchmaur M., Benoit G, Viellefond A, Chevalier A, Lemaigre G, Martin E D, Jardin A. Analysis of mucosal bladder leukocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin. Urol Res, 1989, 17(5): 299–303
Jackson A M, Alexandroff A B, Kelly R W, Skibinska A, Esuvaranathan K, Prescott S, Chisholm G D, James K. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol, 1995, 99(3): 369–375
De Boer E C, De Jong W H, Steerenberg P A, Aarden L A, Tetteroo E, De Groot E R, Van der Meijden A P, Vegt P D, Debruyne F M, Ruitenberg E J. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer immunol Immunother, 1992, 34(5): 306–312
Faber C, Terao E, Morga E, Heuschling P. Interleukin-4 enhances the in vitro precursor cell recruitment for tumor-specific T lymphocytes in patients with glioblastoma. J Immunother (1997), 2000, 23(1): 11–16
Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin-4-deficient mice. J Exp Med, 1999, 189(5): 803–810
Mocellin S, Wang E, Marincola F M. Cytokines and immune response in the tumor microenvironment. J Immunother (1997), 2001, 24(5): 392–407